May 3, 2024, 11:26
Ben Westphalen: The 2nd tumour agnostic, biomarker-driven approval in the EU
Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared a post on X:
“Big news for European cancer patients.
Selpercatinib has been approved by EU Medicines Agency for advanced RET fusion positive solid tumours This marks the 2nd tumour agnostic, biomarker-driven approval in the EU. ”
Read further.
Source: Ben Westphalen/X